ROCHE: A Heavy Weight to give Substance to your Portfolio
maywillow - Tue, 20 Dec 05 :
Roche's Fuzeon/PI more than halves number of patients with detectable HIV
levels
BASEL (AFX) - Roche Holding AG said new interim data on HIV treatment
Fuzeon (enfuvirtide) boosted by protease inhibitor (PI) TMC114/r shows more than
a doubling of the proportion of patients reaching undetectable levels of the
virus.
According to the Swiss drug-maker, the "Fuzeon effect" has also been seen in
other combination trials of Fuzeon and PI, including with lopinavir/r and
tipranivir/r.
This effective strategy for treatment-experienced patients of combining a
boosted PI with FUZEON has been recommended by the US Department of Health and
Human Services (DHHS) guidelines and is anticipated to revolutionise the
management of patients facing HIV resistance.
